Showing 6271-6280 of 9529 results for "".
- Sanofi to Present Data on Dupilumab for BP, AD, CSU, PN, Plus Amlitelimabhttps://practicaldermatology.com/news/Sanofi-Present-Data-Dupilumab-BP-AD-CSU-PN-Plus-Amlitelimab/2471384/Sanofi will present 26 abstracts, including one late-breaking and five additional oral presentations, across approved and investigational medicines at the American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11. Presentations in partnership with Regeneron
- FDA Accepts sNDA for Roflumilast Cream for AD Patients Ages 2-5https://practicaldermatology.com/news/FDA-Accepts-sNDA-Roflumilast-Cream-AD-Patients-Ages-2-5/2471351/The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, for the topical treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, Arcutis Biotherapeutics, Inc. announced. The FDA has se
- Cardio-Dermatology: Multidisciplinary Care Essential for Reducing Multifaceted Riskhttps://practicaldermatology.com/news/cardio-dermatology-multidisciplinary-care-essential-for-reducing-multifaceted-risk/2471287/Chronic skin conditions like psoriasis and atopic dermatitis (AD) are more than skin-deep—they carry significant risks for heart disease and require special attention, according to a compelling presentation given at Masterclasses in Dermatology 2025 in Sarasota. In her talk, Brittany Weber
- Care Urged for Adult-Onset AD Diagnoseshttps://practicaldermatology.com/news/Care-Urged-Adult-Onset-AD-Diagnoses/2471216/As revolutionary as the latest approved therapeutics for atopic dermatitis have been, Daniela Kroshinsky, MD, MPH, cautioned that dermatologists must be vigilant and consider biopsies for atypical or nonresponsive cases before starting dupilumab or a JAK inhibitor. Speaking at the Winter C
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como
- Dupixent Moves Closer to FDA Approval for Bullous Pemphigoidhttps://practicaldermatology.com/news/dupixent-moves-closer-to-fda-approval-for-bullous-pemphigoid/2471173/Dupixent® (dupilumab) significantly improved sustained disease remission in adults with bullous pemphigoid (BP) compared to placebo, according to an announcement from the manufacturers, Regeneron Pharmaceuticals and Sanofi. Acc
- New Dupilumab Data for CSU to Be Presented at AAAAI Meetinghttps://practicaldermatology.com/news/New-Dupilumab-Data-CSU-Be-Presented-AAAAI-Meeting/2471105/New phase 3 data on dupilumab for chronic spontaneous urticaria (CSU) will be among 24 abstracts presented by Sanofi at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California, from February 28 to March 3. The dupilumab CSU data from the LIBER
- Analysis: AI Sensor Reduces Scratching in Atopic Dermatitis Patientshttps://practicaldermatology.com/news/ai-sensor-reduces-scratching-in-atopic-dermatitis/2471104/A wearable sensor utilizing artificial intelligence (AI) with haptic feedback significantly reduced nocturnal scratching in adults with mild atopic dermatitis, a new study reports. Researchers for the single-arm, two-stage cohort study recruited 10 adults (60% female; mean age, 36) with at
- Analysis Finds 'Substantial' Links Between Nail PsO Lesions and Locationshttps://practicaldermatology.com/news/Analysis-Finds-Substantial-Links-Between-Nail-PsO-Lesions-Locations/2471103/A spatial relationship between onycholysis and oil spots, with the intra-nail location of onycholysis being more distal compared to the nearest oil spots, was one of the primary observations in a new analysis of nail psoriasis published in Annals of Dermatology. “Analysis of the Intra-Nail
- Football Star OBJ to Raise Awareness of Seborrheic Dermatitis With Arcutishttps://practicaldermatology.com/news/Football-Star-OBJ-Raise-Awareness-Seborrheic-Dermatitis-With-Arcutis/2471099/NFL star Odell Beckham Jr. will help raise awareness of seborrheic dermatitis as part of a partnership with Arcutis Biotherapeutics, the company announced. “Seb derm is such a common condition, but like me, many people may have a hard time trying to figure out what it is and what can be do